This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

This study is currently recruiting participants.
See Contacts and Locations
Verified November 2016 by Paresh Dandona, University at Buffalo
Solvay Pharmaceuticals
Information provided by (Responsible Party):
Paresh Dandona, University at Buffalo Identifier:
First received: April 27, 2007
Last updated: November 15, 2016
Last verified: November 2016
The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .

Condition Intervention
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism Drug: androgel Drug: placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study

Resource links provided by NLM:

Further study details as provided by Paresh Dandona, University at Buffalo:

Primary Outcome Measures:
  • carotid intima media thickness [ Time Frame: 2 years ]
    carotid intima media thickness

Secondary Outcome Measures:
  • endothelial function [ Time Frame: 2 years ]
    assessed by brachial artery Flow mediated dilatation (FMD%)

Estimated Enrollment: 80
Study Start Date: June 2007
Estimated Study Completion Date: December 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: androgel
Drug: androgel
androgel 1%
Placebo Comparator: placebo
placebo gel
Drug: placebo
Other Name: placebo gel
No Intervention: no treatment
eugonadal comparison arm

Detailed Description:
The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity . This will be done by comparing the changes in several body response indicators following treatment with testosterone in diabetic men with low testosterone levels and comparing them to diabetic men with low testosterone who are not treated with testosterone. These groups will also be compared with diabetic men who have normal testosterone levels

Ages Eligible for Study:   31 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males with age 30-60 years inclusive.
  • PSA < 2.6 ng/ml or < 3.75 ng/ml with a negative prostate biopsy in the last 6 months.
  • IPSS ≤ 19. The lower age limit was decided on the fact that in our study on hypogonadotrophic hypogonadism in type 2 diabetic patients, the youngest subject was 31 years old. The upper age limit has been restricted to 60 to avoid including subjects with significant age-related declines in testosterone concentrations.Subjects on thiazolidinediones, statins, ACE inhibitors, angiotensin receptor blockers or antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the study. Subjects on insulin, metformin or sulfonylureas can participate in the study, provided that minimal changes are made to the doses during the study

Exclusion Criteria:

  • Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks; 2)Hemoglobin A1c >10%;
  • h/o prostate carcinoma;
  • Hepatic disease (transaminase > 3 times normal) or cirrhosis;
  • Renal impairment (serum creatinine > 1.5);
  • HIV or Hepatitis C positive status;
  • Participation in any other concurrent clinical trial;
  • Any other life-threatening, non-cardiac disease;
  • Use of over the counter health supplements which contain androgens;
  • Use of an investigational agent or therapeutic regimen within 30 days of study.
  • Use of testosterone in the past
  • Hematocrit > 50%.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00467987

Contact: Jeanne Hejna 716-898-1950

United States, New York
Diabetes Endocrinology Research Center of WNY Recruiting
Buffalo, New York, United States, 14215
Contact: Paresh Dandona, MD    716-898-1940      
Sponsors and Collaborators
University at Buffalo
Solvay Pharmaceuticals
Principal Investigator: Paresh Dandona Kaleida Health
  More Information

Responsible Party: Paresh Dandona, MD, University at Buffalo Identifier: NCT00467987     History of Changes
Other Study ID Numbers: Androgel 1920
Study First Received: April 27, 2007
Last Updated: November 15, 2016

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents processed this record on August 18, 2017